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Abstract
To better understand the mechanisms of transfor-
mation by the oncogene HER-2, we transduced the
human mammary epithelial (HME) cell line MCF-10A
with HER-2 and developed a cell line that appeared to
moderately overexpress HER-2. These MCF-10HER-2
cells were unable to grow in the absence of epider-
mal growth factor (EGF). However, coexpression of
HER-2 with the HPV-16 oncoproteins E6 and E7 re-
sulted in EGF-independent cells that expressed very
high levels of constitutively activated HER-2. Interest-
ingly, coexpression of E7 with HER-2 resulted in cells
that were EGF-independent for growth but did not ex-
press HER-2 to high levels, and coexpression of E6
with HER-2 resulted in cells expressing higher levels
of HER-2, which were still dependent on EGF for
growth and survival. The MCF-10HER-2E7 and HER-2/
E6E7 cells exhibited constitutive activation of a form
of epidermal growth factor receptor (EGFR) that had
a faster electrophoretic mobility than EGFR activated
by exogenous growth factors. Exposure of cells with
EGFR activation to ZD1839 (Iressa), at concentrations
specific for EGFR, had little or no influence on pro-
liferation of cells with amplified HER-2 but little or
no EGFR. These results indicate that HER-2, E6, and
E7 cooperate with endogenous EGFR to yield fully
transformed cells.
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Introduction
The HER-2 oncogene has been implicated as a causal
factor in breast cancer development for many years. The
clinical data linking the amplification and overexpression
of HER-2 to prognosis [1–3] are supported by laboratory
studies demonstrating a role for HER-2 overexpression
in malignant transformation. In addition, many studies have
examined the HER-2 oncoprotein as a signaling receptor
and have studied its interaction with other members of the
HER family of growth factor receptors [4–14]. Together,
these studies have laid the groundwork for a detailed
mechanistic understanding of how HER-2 overexpression
drives the malignant behavior of human breast cancer cells.
In previous work, we have attempted to understand the
role of HER-2 overexpression and signaling in the progressive
acquisition of growth factor independence exhibited by human
breast cancer cells with a HER-2 gene amplification. Normal
human mammary epithelial (HME) cells, be they primary cul-
tures derived from reduction mammoplasties, spontaneously
immortalized cell lines, or cells artificially immortalized by viral
oncoproteins or telomerase, require multiple growth factors for
continuous survival and proliferation under serum-free con-
ditions in vitro [15–21]. More specifically, these HME cells
require stimulation by an insulin-like growth factor (IGF) and
an epidermal growth factor (EGF)– like factor in the presence
of other nutrients and hormones to proliferate continuously. In-
terestingly, heregulins are unique in their ability to act as either
an insulin-like or EGF-like growth factor toward mammary
epithelial cells [19].
Our previous work in rat models of mammary carcinogen-
esis demonstrated a direct relationship between the progres-
sive acquisition of growth factor independence and malignant
growth potential in vivo [22]. In this rat model, growth factor
independence was mediated by constitutive activation of the
rat homologue ofHER-2, c-neu [23,24]. More recently, we dem-
onstrated a direct correlation between progressive growth fac-
tor independence in human breast cancer cells with a HER-2
amplification and the level of expression of HER-2 [25,26].
In both rat and human models, the acquisition of EGF and
IGF independence was associated with other transformed
phenotypes and with malignant potential in vivo, and multiple
growth factor independence correlated with the overall level
of HER-2 expression at the message and protein levels.
We were able to recapitulate this phenotypic progression
by transducing HME cell lines with a HER-2 retroviral ex-
pression vector, and once again found a direct correlation
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between the level of HER-2 expression and the degree of
growth factor independence exhibited by the cells [26].
Interestingly, when the HER-2 vector was used to infect
the spontaneously immortalized MCF-10A cell line, only
moderate levels of HER-2 expression were obtained, and
the cells were independent of IGF but not EGF. When the
HPV-16– immortalized cell line H16N2 was infected with
the same vector, cells independent of both insulin and EGF
that expressed very high levels of HER-2 emerged, and
these HER-2–transformed cells exhibited a spectrum of
transformed phenotypes [27,28]. Whereas these findings
upheld the correlation between HER-2 expression levels
and multiple growth factor independence, they also sug-
gested that HER-2 can interact with human papilloma virus
(HPV) oncoproteins in important ways. Thus, the present
study was aimed at examining the interaction between
HER-2 and the HPV-16 E6 and E7 viral oncoproteins in
mediating EGF independence. The results reveal important
interactions that provide insights into how HER-2 may re-
quire and interact with other genetic alterations during
breast cancer progression to yield fully transformed cells.
Materials and Methods
Cell Culture
The base medium for all of the cells, except SUM-225,
MDA-361, and MDA-468, was Ham’s F12 media supple-
mented with 0.1% bovine serum albumin, 0.5 mg/ml fungi-
zone, 5 mg/ml gentamycin, 5 mM ethanolamine, 10 mM
HEPES, 5 mg/ml transferrin, 10 mM T3, 50 mM selenium, and
1 mg/ml hydrocortisone. H16N2-pTP, MCF-10HER2, and
MCF-10HER2 E6 cell media were further supplemented
with 10 ng/ml EGF. MCF-10 and MCF-10 E6 cell media
were supplemented with 10 ng/ml EGF and 5 mg/ml insulin.
SUM-190 cell medium was supplemented with 5 mg/ml
insulin. The SUM-225 cell medium was Ham’s F12 sup-
plemented with 0.5 mg/ml fungizone, 5 mg/ml gentamycin,
1 mg/ml hydrocortisone, 5 mg/ml insulin, and 5% fetal bovine
serum (FBS). MDA-361 and MDA-468 cells were grown in
DMEM supplemented with 10% FBS, 0.5 mg/ml fungizone,
and 5 mg/ml gentamycin. Cells infected with retroviral ex-
pression vectors for HPV-16 E6 and HPV E7 were selected
for 2 weeks. All cell culture reagents were obtained from
Sigma Chemical Co. (St. Louis, MO).
Protein Blots
Cells were lysed in a buffer containing 20 mM Tris–HCl,
pH 8.0, 137 mM NaCl, 1% NP-40, 10% glycerol, 1 mM
Na3VO4, 1 mM PMSF, 1% aprotinin, and 20 mg/ml leupep-
tin. Protein concentrations were equalized using the Løwry
method. For whole cell lysates, Laemmli sample buffer
was added and the samples were boiled. For immunopre-
cipitations, 1 mg of antibody was added to 1 mg of sample
and incubated at 4jC for 1 hour. Immune complexes were
then bound to protein A/G beads for 1 hour at 4jC. Immuno-
precipitates were washed three times in lysis buffer. Laemmli
sample buffer was added and the samples were boiled.
Equal amounts of protein were separated by SDS-PAGE.
The proteins were blotted to PVDF membranes and probed
with the antiphosphotyrosine antibody, PY20 (MP Bio-
chemicals, Irvine, CA). Antibodies used for immunoprecipi-
tations were as follows: for HER-2, anti–HER-2 clone Ab-17
(Labvision, Fremont, CA); for epidermal growth factor recep-
tor (EGFR), anti–EGFR clone Ab-5 (CalBiochem, LaJolla,
CA); and for Her-3, anti–Her-3 clone Ab-4 (Labvision). All
blots were repeated at least twice.
EGFR Multiplex Westerns
EGFR was immunoprecipitated as above. The immuno-
precipitates were loaded on one lane across the top of a
7.5% SDS-PAGE gel, separated, and blotted to PVDF mem-
brane. The membrane was loaded in a Miniblotter 28 (Immu-
netics, Cambridge, MA) and antibodies to different EGFR
tyrosine phosphorylation sites (Cell Signaling, Beverly, MA
and Biosource, Camarillo, CA) were used to probe different
lanes of the membrane. Multiplex Westerns were repeated
at least three times.
Propidium Iodide (PI) Staining
PI staining was used to determine cell cycle stage dis-
tribution and sub-G1 fraction of cycling cells. Cells were
released from the plate by trypsinization, washed three times
with PBS, fixed with 70% EtOH for 20 minutes at room
temperature, and washed with PBS again. An amount of
0.1 ml of RNAse (1 mg/ml in PBS) was added for 30 minutes
at 37jC. Cells were stained with PI (50 mg/ml in PBS) for
at least 15 minutes and sorted. PI staining was done at
least twice.
Growth and Survival Curves
For growth factor depletion/addition or growth with Iressa
assays, cells were plated at 3.5  105 in triplicate in six-well
plates. Plating efficiencies were obtained on day 1 after
plating, after which the growth factors were removed from
the media, and 2 ng/ml heregulin-b was added to the appro-
priate cells. Cells in complete media and cells in growth
factor–depleted media were counted on day 7 after plating.
For survival assays, cells were grown in their appropriate
medium for 7 days, then switched to growth factor–depleted
mediumor growth factor–depletedmediumcontaining 2 ng/ml
heregulin-b. All cell counts were performed using a Coulter
model Z1 (Coulter Corporation, Miami, FL).
Results
The Influence of HPV-16 E7 and E6 on HER-2 Expression
and Growth Factor Independence
In previous studies, we demonstrated that the degree of
growth factor independence of human breast cancer cells
with a HER-2 gene amplification, and HME cells infected
with a retroviral HER-2 expression vector, is proportional to
the level of HER-2 protein overexpression [25,26]. Because
the fully transformed H16N2-HER-2 cells were originally
immortalized by infection with the HPV-16 viral oncoproteins
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E6 and E7, whereas the more moderately transformed MCF-
10AHER-2 cells were derived from a spontaneously im-
mortalized cell line, we sought to determine if infection of
MCF-10HER2 cells with HPV-16 E7 and/or E6 would result in
higher levels of expression of HER-2, and subsequent
escape from their requirement for EGF. Accordingly, MCF-
10HER2 cells or MCF-10A controls were infected with ret-
roviral vectors for HPV-16 E7, E6, or both E6 and E7, and
tested directly for the acquisition of EGF-independent growth
capacity by direct selection in EGF-free medium. Table 1
shows the result of this experiment and indicates that MCF-
10HER2 cells infected with the E6 retroviral vector failed
to grow in EGF-free medium. By contrast, deletion of EGF
from the medium of MCF-10HER2 cells infected with the
E7 retroviral vector resulted in the emergence of numerous
EGF-independent colonies that expanded slowly and also
produced floating cells in the medium. Interestingly, MCF-
10HER2 cells infected with both E6 and E7 vectors gave
rise to many EGF-independent colonies that expanded rap-
idly, were readily subculturable, and did not produce float-
ing cells. Infection of control MCF-10A cells with E7, E6,
or both viral oncogenes never resulted in the emergence
of EGF-independent cells, as shown in Figure 1. Thus, the
MCF-10HER2/E6E7 cells expressed the same phenotype
of EGF independence as the H16N2HER2 cells, indicating
that HER-2 and HPV E6/E7 can cooperate to yield cells that
are fully growth factor– independent.
Because early-passage MCF-10HER-2/E7 cells grew
slowly as a population and produced many floating cells
in EGF-free medium, we analyzed the cell cycle stage dis-
tribution of these cells and the MCF-10HER-2/E6E7 cells,
which were growing much more rapidly. Figure 2A shows
the difference in the growth rate of the population of MCF-
10HER-2/E7 cells compared to that of the HER-2/E6E7 cells,
and also shows the results of the flow cytometry analysis.
Because the cell cycle stage distribution was essentially
the same in both populations, but the doubling times of the
two cell types were very different, we hypothesized that the
MCF-10HER-2/E7 cells were undergoing EGF-independent
cell cycle progression similar to the HER-2/E6E7 cells, but
were much less able to survive under these conditions and,
as a result, were producing floating cells in the medium.
Confirmation that floating cells present in the medium of
the MCF-10HER2-E7 cells were apoptotic was obtained by
flow cytometric analysis, which demonstrated that floating
cells had sub-G1 DNA content, whereas the attached cells
retained a normal DNA histogram (Figure 2B). Not surpris-
ingly, the apoptosis that occurred under EGF-free conditions
was relieved by HPV-E6 expression, which is known to dis-
rupt p53 function in normal cells, and similar phenomena
Table 1. Emergence of EGF-Independent Colonies Following Transduction
of MCF-10A Cells or MCF-10HER2 Cells with HPV-16 E7, E6, or E6 and E7
Expression Vectors.
Colonies Emerging in EGF-Free Medium
Control E6 E7 E6/E7
MCF-10A None* None None None
MCF-10HER2 None None Many/floatingy Manyz
*No colonies emerged after 4 weeks in EGF-free medium.
yMany colonies emerged in EGF-free medium. Colonies shed floating cells
into the medium.
zMany colonies emerged in EGF-free medium. No floating cells were shed.
Figure 1. EGF requirement for growth of MCF-10A cells and their E6- and E7-transduced derivatives. The control cell lines for these experiments include MCF-10A
cells themselves, MCF-10AE6 cells, MCF-10AE7 cells, and MCF-10AE6E7 cells. To examine the EGF dependency of these control cell lines, cells were plated at
low density in serum-free medium, cultured for 8 days in the presence or absence of EGF, and counted. Data indicate the mean number of cells per plate for
triplicate plates, and the error bars indicate the range in the data.
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have been observed in other experimental systems [29,30].
It is important to note that the growth rate of the MCF-
10HER2/E7 cell population in EGF-free medium increased
with time in culture such that by after approximately 10 pas-
sages in EGF-free medium, these cells were growing as rap-
idly as the cells infected with both the E7 and E6 constructs
and no longer produced floating cells in the medium. The
growth curves for the late-passage MCF-10HER2/E7 cells
compared to the HER-2/E6E7 cells are shown in Figure 2C.
At present, there is no evidence that the MCF-10HER2/E7
cells acquired alterations in p53 that explain their increased
growth rate with passage. Rather, our data suggest that the
levels of activated EGFR increased steadily with passage,
resulting in a level of EGF-independent EGFR signaling that
was sufficient to maintain viability and cell cycle progression.
Western blot analysis (Figure 3) of the expression levels
of HER-2 in the MCF-10HER2 cell lines and their E6/E7
transduced derivatives demonstrated that MCF-10HER-2/
E6 cells expressed higher HER-2 levels than the EGF-
independent HER-2/E7 cells. The highest HER-2 expression
levels were found in the cells infected with both E6 and E7.
Thus, the level of HER-2 expression did not directly correlate
Figure 2. Growth of MCF-10HER2 cells expressing HPV-16 E7 or E6E7 in EGF-free medium. (A) Cells were infected with retroviruses carrying the E7 and/or E6
genes of HPV-16, EGF was withdrawn, and the cells remaining on the plate were counted. MCF-10HER2 cells or MCF-10HER2/E6 cells did not grow in EGF-free
medium. PI staining was performed on actively growing cells to obtain a cell cycle analysis. MCF-10HER2/E7 cells appeared to grow slower than MCF-10HER2/
E6E7 cells; however, both cell types exhibited similar cell cycle stage parameters. (B) DNA histograms of MCF-10HER-2/E7 cells attached to the dish and floating
in the medium compared to MCF-10AHER-2 cells growing with EGF, or to the EGF-independent MCF-10HER-2/E6E7 cells. Indicated cells were stained with PI
and analyzed by flow cytometry. Note that the G1 peak for the attached cells and fully EGF-independent cells occurs at approximately channel 400. A G1 peak at a
similar channel is seen in the floating cell population; however, a large fraction of this population is present in a sub-G1 peak that occurs between channels 200 and
350. (C) MCF-10HER2/E7 cells after 10 passages in EGF-free medium were grown without EGF for the indicated days and counted. Late-passage MCF-10HER2/
E7 cultures grew at the same rate as MCF-10HER2/E6E7 cultures.
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with growth factor independence. Rather, coexpression of
HER-2 with E7 was able to drive EGF-independent prolifer-
ation, whereas coexpression of HER-2 with E6 resulted in
higher overall levels of HER-2 expression. Thus, combining
HER-2 with both E6 and E7 yielded EGF-independent cells
expressing very high levels of HER-2.
EGF and -Heregulin Dependence for Growth and Survival
of MCF-10HER2 Cells and Their Derivatives
The results described above prompted experiments
aimed at further defining the influence of HER-2, E6, and
E7 on the requirements for EGF or b-heregulin on the growth
and survival of MCF-10A cells. To measure the effect of
these growth factors on cell proliferation, cells were seeded
at low density and the media changed 24 hours later to
defined media supplemented with or without EGF, or in
EGF-free medium supplemented with b-heregulin, and cells
were counted 7 days later (Figure 4A). To assess the sur-
vival effects of these growth factors, cells were seeded at
low density, cultured for 7 days in their regular medium, and
then switched to defined medium containing the same factor
combinations as above, and then counted 7 days later
(Figure 4B). The data shown in Figure 4, A and B demon-
strate that MCF-10HER2 cells are dependent on EGF for
both growth and survival, as both experiments showed a net
cell loss over the culture period in the absence of EGF.
Further, replacement of EGF with b-heregulin yielded only
small increases in cell number, indicating that even when
HER-2 is moderately overexpressed, heregulin is a relatively
weak EGF-like growth factor, consistent with our previously
published results [19]. MCF-10HER2/E6 cells showed an
even greater dependency on EGF for survival than control
MCF-10 or MCF-10HER-2 cells, but the E6-transduced cells
also had a more robust response to b-heregulin. This result is
consistent with the elevated levels of HER-2 expressed by
the E6-transduced cells (Figure 5A). The MCF-10HER2/E7
cells were able to survive and proliferate in EGF-free me-
dium, and these cells were also responsive to addition of
either EGF or b-heregulin to the medium. Finally, MCF-
10HER2/E6E7 cells were completely independent of EGF,
and did not respond to exogenous EGF or b-heregulin with
increased growth or improved survival.
Expression and Activation of EGFR, HER-2, and HER-3
in MCF-10HER2 Cells and Their Derivatives
To compare the growth and survival responses of the
HER-2–overexpressing MCF-10A cell populations to the
expression and activation status of HER-1, HER-2, and
HER-3 in these cells, immunoprecipitation/Western blot
analysis experiments were performed and the results are
shown in Figure 5A. Consistent with their EGF dependence,
MCF-10HER2 cells only expressed high levels of tyrosine-
phosphorylated EGFR when cultured in the presence of
EGF, and the levels of activated HER-2 and HER-3 in
these cells were higher than in vector control cells. Tyrosine-
phosphorylated HER-2 was increased slightly in the pres-
ence of EGF, and tyrosine-phosphorylated HER-3 was
slightly elevated in the presence of heregulin. By contrast,
the fully EGF-independent MCF-10HER2/E6E7 cells ex-
pressed high levels of activated EGFR, HER-2, and HER-3
regardless of the presence or absence of growth factors.
MCF10HER2/E6 cells had elevated levels of HER-2 expres-
sion and activation, yet EGFR activation was only main-
tained to high levels in the presence of EGF, consistent
with their EGF dependency. The elevated levels of acti-
vated HER-2 in these cells are also consistent with their en-
hanced responsiveness to b-heregulin, as noted earlier. The
results obtained with the MCF-10HER2/E7 cells were most
interesting. These cells, which are the minimally perturbed
cells that acquired EGF independence, expressed only mod-
erate levels of activated HER-2, but expressed constitutively
tyrosine-phosphorylated EGFR when grown in the absence
of EGF. Furthermore, the electrophoretic mobility of the
activated EGFR in both the MCF-10HER2/E7 cells and
MCF-10HER2/E6E7 cells was consistently faster than for
the cells cultured in the presence of EGF. The data shown
in Figure 5B demonstrate that the MCF-10HER2/E7 cells, in
addition to overexpressing HER-2, also expressed elevated
levels of EGFR compared to their EGF-dependent counter-
parts. Thus, acquisition of EGF independence was associ-
ated with increased EGFR protein expression. Figure 5C
shows that activated EGFR in the cells grown in EGF-free
medium has fewer specific phosphotyrosine sites than the
cells grown with EGF. Notably, phosphorylation of tyrosine
1045, the c-cbl–binding site that is responsible for ubiquiti-
nation of EGFR [31], was consistently absent in the EGF-
independent cells. Differential tyrosine phosphorylation of
EGFR in the EGF-dependent versus the independent cells
could explain, at least in part, the faster electrophoretic mo-
bility of activated EGFR that occurs in the absence of exo-
genous growth factor.
Taken together, these results suggest that expression of
HER-2 and E7 acts to mediate the EGF independence
phenotype, which is driven by the constitutive activation of
EGFR. It is important to note that this interpretation stands
in contrast to the mechanism suggested by the previously
published correlative data, which indicated that HER-2 ex-
pression levels were the primary driver of EGF-independent
growth. The current data now demonstrate that, whereas
high HER-2 levels can augment the EGF independence
phenotype, high HER-2 levels alone are insufficient to make
Figure 3. HER-2 expression levels in control MCF-10A cells, and in MCF-
10HER-2 cells with E6, E7, or both. Whole cell lysates from the panel of cell
lines were separated on 7.5% SDS-PAGE, blotted, and probed with anti –
HER-2 antiserum. Blots were also probed with antiactin antibody to control
for loading.
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cells EGF-independent. Rather, molecular alterations in-
duced by the HPV-16 E7 oncoprotein lead to the constitutive
activation of EGFR that is required for EGF-independent
proliferation, and this interaction requires the presence of
elevated levels of HER-2.
Role of EGFR Versus HER-2 Activation for Growth and
Survival of HER-2–Overexpressing Cells
To examine further the separate roles of EGFR and HER-2
in mediating the EGF independence phenotype, experi-
ments were performed in which the MCF-10HER2 cells and
their derivatives were exposed to concentrations of ZD1839
(Iressa) that are able to block EGFR activation while having
little or no effect on HER-2 tyrosine phosphorylation [32–34].
To confirm the appropriate concentrations of ZD1839 to use
for these experiments, MDA-361 cells, which overexpress
HER-2 but do not express EGFR, and MDA-468 cells, which
overexpress EGFR but do not express HER-2, were ex-
posed to varying concentrations of ZD1839 and analyzed
24 hours later for HER-2 or EGFR tyrosine phosphorylation
(Figure 6A). These experiments demonstrated that expo-
sure of MDA-468 cells to 0.5 mM ZD1839 resulted in the
complete loss of tyrosine-phosphorylated EGFR, and had
little or no effect on HER-2 tyrosine phosphorylation in the
Figure 4. Growth and survival of various cells ± EGF or + heregulin (HRG). (A) To analyze cell proliferation, cells were plated in the indicated media and three
plates were counted on day 1; the remaining plates were counted on day 7. (B) To estimate the influence of growth factors on cell survival, cells were plated and
allowed to grow for 7 days, and then counted. Cells were then switched to experimental media, cultured for another 7 days, and then counted. Bars indicate the
mean number of cells per 35-mm well and the error bars indicate the range in the data.
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MDA-361 cells. Similarly, exposure of the EGF-independent
MCF-10HER2/E6E7 cells to ZD1839 under the same
conditions resulted in a complete loss of activated EGFR,
but little or no reduction in tyrosine-phosphorylated HER-2.
Experiments were next performed to evaluate the activation
status of EGFR and HER-2 in the MCF-10HER2 cells and
their E6- and E7-transduced counterparts following exposure
to 0.5 mM ZD1839 for 48 and 72 hours. Two breast cancer
cell lines with a HER-2 gene amplification that express
different levels of EGFR were included in this analysis (SUM-
190 and SUM-225). The data in Figure 6B show that expo-
sure of MCF-10HER2/E7 cells and MCF-10HER2/E6E7
cells to 0.5 mM ZD1839 resulted in the complete loss of
EGFR tyrosine phosphorylation but only partially reduced
HER-2 phosphorylation. Similar results were obtained with
the SUM-190 and SUM-225 cells. We next examined the
effect of daily administration of 0.5 mM ZD1839 on the growth
of these EGF-independent cell lines. The data in Figure 6C
show that 0.5 mM ZD1839 was able to completely inhibit
the growth of MCF-10HER2/E7 cells, MCF-10HER2/E6E7
cells, and SUM-225 cells, whereas SUM-190 cells were only
partially growth-inhibited by this concentration of ZD1839.
These results are consistent with the Western blot results
shown in Figures 3A and 5A, and demonstrate that the EGF-
independent growth phenotype in MCF-10HER2/E7 cells
and MCF-10HER2/E6E7 cells is primarily the result of the
constitutive activation of EGFR that occurs in the context of
HER-2 and E7 expression. EGF-independent growth of the
SUM-225 human breast cancer cells, which express high
levels of EGFR in addition to HER-2, is also driven primarily
by EGFR. However, the SUM-190 breast cancer cells that
overexpress HER-2 but express relatively low EGFR levels
were much less affected by ZD1839 concentrations that
preferentially inhibit EGFR signaling, whereas the EGFR-
negative, HER-2–amplified MDA-361 cells were unaffected
by ZD1839.
Discussion
The HER-2 oncogene undoubtedly plays an important role
in breast cancer progression in a significant fraction of cases.
However, HER-2 becomes amplified and overexpressed in a
broader genetic context, and genetic and epigenetic alter-
ations that accompany HER-2 gene amplification are very
likely to interact with HER-2 to mediate the complete trans-
formed phenotypes expressed by breast cancer cells. It is
Figure 5. Analysis of erbB receptors in MCF-10HER-2 and derivative cell
lines. (A) HER-2, EGFR, and HER3 were immunoprecipitated, separated
on 7.5% SDS-PAGE, blotted, and probed for P-Tyr. Nonspecific bands (NSB)
from the blots are shown to indicate equivalent loading of immunopre-
cipitates per cell type within the experiments. (B) HER-2 and EGFR were
immunoprecipitated, separated on 7.5% SDS-PAGE, blotted, and probed
for HER-2 or EGFR. Nonspecific bands (NSB) from the blots are shown to
indicate equivalent loading of immunoprecipitates within each experiment.
(C) EGFR was immunoprecipitated from the indicated cells. The proteins
from one immunoprecipitation were electrophoresed, blotted, and fixed in a
multiplex blotting apparatus. The immunoprecipitate was probed with anti-
bodies to the indicated EGFR phosphotyrosines.
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known from clinical studies that the prognostic significance
of HER-2 overexpression is influenced by other factors,
specifically the EGFR and p53 status of the breast cancers
[35–38]. Indeed, one can make the argument based on the
literature that the overexpression of HER-2, EGFR, and
mutant p53 combines to yield highly aggressive breast
cancer cells [39].
In previous work, we set out to recapitulate in immortal-
ized HME cells the HER-2 expression levels found in human
breast cancer cells with a HER-2 gene amplification. We
found that the only way to accomplish high-level HER-2 over-
expression was to transduce HER-2 into cells that were also
engineered to coexpress HPV-16 viral oncoproteins [26].
Thus, the cells that we eventually obtained were similar to
breast cancer cell lines such as SKBR3, SUM-190, SUM-
225, 21MT1, and 21MT2 that express high levels of HER-2.
Interestingly, these breast cancer cell lines also express
EGFR and mutant p53. Further studies with the high-level
HER-2 overexpressers demonstrated that the altered signal-
ing that resulted from HER-2 overexpression in this context
Figure 6. Effects of blocking EGFR on HER-2 activation. (A) MDA-361 cells (containing HER-2 and not EGFR), MDA-468 cells (containing EGFR and not HER-2),
and MCF-10HER2/E6E7 cells were treated with DMSO or 0.1, 0.5, or 1.0 M Iressa. HER-2 and EGFR were immunoprecipitated, separated on 7.5% SDS-PAGE,
blotted, and probed for PTyr. At a concentration of 0.5 M, Iressa had no effect on HER-2 activation, whereas that concentration abrogated EGFR activation. (B)
Cells were treated with DMSO or 0.5 M Iressa for 48 or 72 hours. HER-2 and EGFR were immunoprecipitated, separated on 7.5% SDS-PAGE, blotted, and
probed for PTyr. Nonspecific bands are once again presented to show an equivalent loading of immunoprecipitates from each experiment. (C) Cells were plated
and a sample was counted at day 1. Another sample was treated with 0.5 M Iressa or DMSO for 5 days and counted.
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was directly responsible for the phenotypes of growth factor–
independent proliferation, anchorage-independent growth,
motility, and invasive capacity [26,27,40,41]. The results ob-
tained from the current studies now allow us to begin to ex-
amine the relative contribution of HER-2, EGFR, E7, and E6
on the expression of the completely transformed phenotypes
described above.
Data from the clinical literature indicate that amplification
of HER-2 in the setting of EGFR positivity results in more
aggressive disease than when HER-2 is amplified in EGFR-
negative cells [37,38]. A number of laboratory studies have
examined the potential for interaction between HER family
members, and it has become widely accepted that HER-2
is the preferred heterodimerization partner for EGFR and
HER-3, and that the HER-2 oncoprotein largely acts as a
signaling coreceptor [6–9]. However, most of the studies
on which this interpretation is based were performed in
highly artificial systems using cells engineered to express
equivalent levels of HER family members. Thus, these ex-
periments did not take into account the fact that, in most
breast cancers, widely different levels of HER family mem-
bers that can have a significant impact on signaling are
expressed. Recently though, Hendriks et al. [42] examined
this question, and their results help us to interpret our data
in light of the widely different levels of EGFR and HER-2
expressed in our cell lines. From their data, as well as our
own, a model begins to emerge in which the relative pro-
portion of EGFR homodimers, EGFR/HER-2 heterodimers,
HER-2/HER-3 heterodimers, and HER-2 homodimers de-
pends on the relative expression of each of the receptors in
different cells. In cells that express low levels of p185HER-2,
such as normal mammary epithelial cells and MCF-10A
cells, EGFR homodimers that are activated by EGF and
other ligands of the family predominate. As HER-2 levels
increase, EGFR/HER-2 heterodimers begin to predominate
such that when HER-2 is overexpressed relative to EGFR,
the majority of EGFR molecules are associated with HER-2.
As HER-2 levels increase still further, as is the case when
the HER-2 gene becomes amplified, the absolute levels of
HER-2 homodimers increase, and these homodimers can
come to represent the majority of the signaling complexes
in cells with a HER-2 gene amplification. The Western blot
data shown in Figure 6 are consistent with such a model,
and indicate that when ZD1839 is used at concentrations
specific for EGFR, tyrosine-phosphorylated EGFR becomes
undetectable, but the levels of tyrosine-phosphorylated
HER-2 are only decreased slightly. We interpret this finding
to indicate that ZD1839 at 0.5 mM blocks the activity of EGFR
associated with HER-2 in heterodimers, but has little or no
effect on the activity of HER-2 homodimers. Thus, SUM-225
breast cancer cells that express high levels of EGFR are
completely growth-inhibited by ZD1839 at these concen-
trations, whereas the SUM-190 cells, which express lower
levels of EGFR, are only partially inhibited. MDA-361 cells,
which do not express EGFR at all, are unaffected by
ZD1839. With regard to the SUM-225 cells, it is noteworthy
that exposure of these cells to 0.5 mM ZD1839 was able to
block proliferation, but appeared to have no effect on sur-
vival. This is in stark contrast to the effect that the pan-erbB
kinase inhibitor, CI-1033, has on SUM-225 cells. Exposure of
SUM-225 and SUM-190 cells to 0.1 to 1.0 mM CI-1033
eliminates tyrosine phosphorylation of EGFR, HER-2, and
HER-3, and elicits both growth arrest and a profound apop-
totic response (Molecular Cancer Therapeutics, in prepa-
ration). Thus, we propose that in cells expressing both
HER-2 and EGFR, heterodimeric complexes of these re-
ceptors play an important role in driving cell cycle progres-
sion, and that activation of HER-2 homodimers plays an
important role in mediating survival. Experiments are un-
derway to directly test this hypothetical model.
The interaction of HER-2 overexpression with the HPV-16
oncoproteins E7 and E6 is interesting and likely reflects
important cooperating genetic events that occur during
breast cancer progression. Similar observations have re-
cently been made using an oral epithelial cell model system
in which E6 and E7 enhanced the transforming potential
of HER-2 [43]. In past studies, we found that breast cancer
cell lines with a HER-2 gene amplification express levels
of HER-2 message and protein 10 to 50 times higher than
physiological levels. It is probably not coincidental that all of
these cell lines have p53mutations, and our experiments with
HER-2–transduced cells showed that coexpression of HBV-
16 E6 resulted in elevated levels of tyrosine-phosphorylated
p185HER-2. We do not yet know the mechanism by which
p53 inactivation results in enhanced expression of HER-2
protein. We do know that expression of HPV-16 E6 and E7
resulted in increases in HER-2 mRNA levels without influ-
encing the copy level of the transgene (data not shown).
Thus, it is possible that loss of functional p53 relieves some
negative constraints on HER-2 gene transcription. Alterna-
tively, expression of very high HER-2 levels could induce a
growth arrest or apoptotic signal that prevents cells from
expressing very high levels of HER-2 in the context of wild-
type p53.
The cooperation of HER-2 with HPV-16 E7 to yield
the growth factor independence phenotype is particularly
intriguing. Expression of E7 in the context of HER-2 over-
expression results in the growth factor– independent acti-
vation of EGFR, which is the primary driver of cell growth.
Because E7 only induces EGF independence in the context
of HER-2 overexpression, we hypothesize that activated
EGFRs in these cells are in heterocomplexes with HER-2.
Indeed, activation of EGFR as a heterodimer with HER-2
likely explains the differential phosphorylation on specific
tyrosines, and the molecular weight shift that we have
observed in growth factor– independent cells. Future experi-
ments will seek to determine the proximate mechanisms of
EGFR activation in HER-2– and E7-expressing cells. In
addition, it will be very important to determine what aspect
of breast cancer progression is being mimicked by E7 ex-
pression in our experimental system. Based on our cur-
rent understanding of the transforming properties of E7, the
most likely candidates are centered around the Rb path-
way of cell cycle regulation [44]. Some breast cancer cells
lose the expression of p21 and p27 during cancer progres-
sion [35,45,46]. Other breast cancer cells overexpress
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cyclin D1 either as a result of gene amplification or tran-
scriptional activation of the gene [47–51]. Although rare,
some breast cancer cells have point mutations in the Rb
gene itself [52]. These observations have prompted some
investigators to argue that genetic alterations epistatic to
the Rb pathway occur in virtually all cancer cells [30]. There-
fore, all of these genetic alterations are candidates to be
tested for their interaction with HER-2 in mediating the
growth factor independence phenotype. Thus, we hypo-
thesize that expression of HPV-16 E7 in our experimental
system mimics one or more of the genetic alterations epi-
static to the Rb pathway, which occur in different types of
breast cancers and which interact with HER-2 to drive
cell transformation.
In summary, the results of experiments in which we
have attempted to recapitulate the transformed phenotypes
expressed by breast cancer cells with a HER-2 gene ampli-
fication have led us to appreciate better how HER-2 over-
expression cooperates with other genetic alterations to yield
complete malignant transformation. Future studies will be
aimed at teasing apart the individual contributions of HER-2,
EGFR, p53, and RB in driving the expression of altered
phenotypes. These studies will help us to understand better
the transforming function of HER-2 gene amplification when
present in different genetic contexts. Such an understanding
will be important for determining the true prognostic signifi-
cance of HER-2 overexpression and for predicting the re-
sponse of breast cancer cells from different patients to
specific targeted therapeutics.
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